Miguel Ángel Gómez Bravo-rekin lankidetzan egindako argitalpenak (7)

2024

  1. The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis

    Liver International, Vol. 44, Núm. 2, pp. 279-285

2022

  1. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation

    American Journal of Transplantation, Vol. 22, Núm. 6, pp. 1671-1682

  2. Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 6, pp. 335-342

  3. Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study

    Liver Transplantation, Vol. 28, Núm. 7, pp. 1257-1261

2018

  1. Influence of donor liver CYP3A4∗20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients

    Pharmacogenetics and Genomics, Vol. 28, Núm. 2, pp. 41-48

  2. Prevalence and progression of chronic kidney disease after liver transplant: a prospective, real-life, observational, two-year multicenter study

    Revista Española de Enfermedades Digestivas, Vol. 110, Núm. 9, pp. 538-543

2013

  1. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in caucasian spanish liver transplant patients

    Journal of Clinical Pharmacology, Vol. 53, Núm. 11, pp. 1146-1154